Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Study of Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 Negative Postmenopausal Metastatic Breast Cancer Patients

NCT02383030 is registered in ClinicalTrials.gov with Consorzio Oncotech as lead sponsor.

NCT NCT02383030
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02383030 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Study of Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 Negative Postmenopausal Metastatic Breast Cancer Patients
Lead sponsor
Consorzio Oncotech
Phase
Phase 3
Overall status
Unknown status
Start date
November 30, 2015
Completion date
December 31, 2017
Enrollment
156 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer